Articles from Tr1X, Inc.

Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease company developing Type 1 regulatory T (Tr1) cell therapies, today announced two oral presentations at the American Society of Gene and Cell Therapy Annual Meeting 2026, May 11-15, 2026, in Boston.

On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company an $8 million grant to support its ongoing Phase 1/2a clinical trial of TRX103, an engineered Tr1 Treg cell therapy for use in the prevention of graft-versus-host disease (GvHD) in blood cancer patients undergoing mismatched stem cell transplants. This award follows a $4 million CIRM grant received by Tr1X in early 2024 for late-stage preclinical research that helped to advance TRX103 to human trials.

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced a planned leadership transition in which co-founder and Chief Operating Officer David de Vries will succeed Bill Lis as Chief Executive Officer, effective June 1, 2025. Mr. Lis will become Executive Chairman of the Board of Directors.